Status:

COMPLETED

Group B Streptococcus Response After Probiotic Exposure

Lead Sponsor:

University of New Mexico

Collaborating Sponsors:

Marquette University

Conditions:

Group B Strep Infection

Eligibility:

FEMALE

18+ years

Phase:

PHASE3

Brief Summary

This is an open-label randomized control trial and feasibility study designed to determine the feasibility of a larger RCT in our setting that would examine prenatal probiotic use in Group B Strep (GB...

Detailed Description

This is an open-label randomized control trial and feasibility study designed to determine the feasibility of a larger RCT in our setting that would examine prenatal probiotic use in Group B Strep (GB...

Eligibility Criteria

Inclusion

  • • Healthy adult (≥ 18 years of age) pregnant women who are 36 - 37 6/7 weeks gestation at enrollment \[calculated from the first day of Last Normal Menstrual Period (LNMP) and/or ultrasound (US)\]
  • Group B Streptococcus Positive at 36 weeks gestation with:
  • No obstetric complication requiring delivery prior to 39 weeks (hypertensive disorder diagnosed prior to enrollment, gestational diabetes, multiple gestation)
  • No fetal complication (e.g., birth defect, intrauterine growth restriction)
  • No medical complication (e.g., chronic hypertension, preexisting diabetes mellitus)
  • Who do not currently ingest an over the counter probiotic supplement (not including yogurt)
  • Who can both speak and read English or Spanish
  • Pregnant women who regularly attend UNM prenatal clinics for their prenatal care ("regularly attend" will be defined as starting prenatal care prior to 20 weeks gestation and missing no more than one prenatal appointment during this pregnancy)
  • No hypersensitivity reaction to β-lactam antibiotics

Exclusion

  • Those less than 18 years of age
  • Non-pregnant women
  • Later in pregnancy than 38 weeks gestation at enrollment \[per LNMP and/or US\]
  • Those with an obstetric, fetal or medical complication of pregnancy
  • Group B Streptococcus negative at 36 weeks gestation. Those ineligible for testing at 36 weeks gestation (history of GBS bacteriuria during the current pregnancy or have previously given birth to a GBS affected child.) We will not exclude those with bacteriuria other than GBS, and we will not exclude women who have taken an antibiotic during pregnancy, but we will track this as it is addressed in the Questionnaire for Women.
  • Women who are currently ingesting an over the counter probiotic supplement (except for yogurt)
  • Women who do not have electricity in the home.
  • Women who are planning an elective repeat cesarean birth
  • Women who do not speak and read English or Spanish
  • Women with a history of missing one or more scheduled prenatal visit during this pregnancy
  • Hypersensitivity reaction to β-lactam antibiotics

Key Trial Info

Start Date :

December 24 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2023

Estimated Enrollment :

68 Patients enrolled

Trial Details

Trial ID

NCT04721912

Start Date

December 24 2020

End Date

August 31 2023

Last Update

January 14 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of New Mexico Hospital

Albuquerque, New Mexico, United States, 87112